enGene Therapeutics Inc. (ENGN) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
No case yet. It builds on the next filing, report or 13F period.
enGene Therapeutics Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
tall tick = annual report · 1 on record
ENGN (enGene Therapeutics Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
enGene Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
High 1.91 at 3:45 pm ET, low 1.90 at 11:00 am ET.
56 managers report a position worth $67.5M between them, and 12 of them hold 80% of it.